Current guidelines support culprit-only PCI in these cases, but the “hypothesis-generating” results suggest taking a closer ...

A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.

A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros ...

This month: shingles vaccine cuts CV events, brain injury impacts stroke risk, food insecurity’s health legacy, and more.

Tailoring the number of consults based on HF severity, which can be assessed pragmatically, could pay dividends, say ...

The results have implications not only for resource-limited parts of the world, but also for wealthier countries, one expert ...

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.

STEMI criteria alone aren’t perfect for identifying occluded arteries, but still some question the need for a new paradigm.

In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...

May 15, 2025 | Philippe Généreux, Brad Oldemeyer, and Jennifer Daniel share their experiences treating asymptomatic aortic stenosis patients in the EARLY TAVR trial. Listen to previous episodes ...

Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.